Can a cancer drug stop lung cancer before it starts?
NCT ID NCT03634241
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent lung cancer in 45 people with high-risk lung nodules or early-stage non-small cell lung cancer. Participants received pembrolizumab intravenously, and researchers tracked tumor response and survival. The goal was to see if the drug could shrink or stabilize nodules and prevent progression to full-blown cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (Keytruda)
- What this could lead to
- If successful, this could point toward a way to prevent lung cancer from developing in people with suspicious lung nodules.
- What could go wrong
- This is a small, early-phase trial with only 45 participants and no comparison group, so results may not apply broadly. Pembrolizumab can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radiation hotspots may boost lung cancer treatment — a trial puts it to the test
- Could a simple assessment help older lung cancer patients tolerate chemo better?
- Could a muscle relaxant help fight lung cancer? scientists test papaverine with standard therapy
- Could lung cancer patients get immunotherapy less often?
- New combo aims to stall lung Cancer's spread
- Heart monitor reveals hidden damage from cancer radiation